GT Biopharma Inc (GTBP) Stock Analysis

Verdict: AVOID

Binary trial dependence and a 6-month cash runway make this a high-risk dilution candidate despite a 39% relief rally.

Investment score: 22/100

Analysis as of 2026-06-26

Is GT Biopharma Inc stock worth reviewing? AI model thesis

The AI model avoids GTBP due to an imminent cash crunch, a track record of severe earnings misses, and a 1-employee operational structure that lacks the scale for commercialization without a partner.

7-factor investment score

Valuation: 30/100 (weight 20%)
Financial Health: 10/100 (weight 15%)
Technical Momentum: 35/100 (weight 15%)
Earnings Quality: 5/100 (weight 15%)
Insider Sentiment: 40/100 (weight 10%)
Analyst Consensus: 45/100 (weight 10%)
Risk-Adjusted Return: 15/100 (weight 15%)

GT Biopharma Inc opportunities and risks

What speaks for GTBP

TriKE Platform Scalability

What speaks against GTBP

Terminal Cash Runway Expiry

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
GTBP	n/a	0.0x	0.1x	0.0%	0.0%	-284.5%
ALLR	n/a	60.0x	n/a	107.5%	-3260.6%	-80.7%
CLRB	n/a	0.0x	n/a	0.0%	0.0%	-231.1%
PTN	n/a	23.1x	n/a	99.8%	-48.5%	-5.0%
OTLC	0.1x	0.0x	48.7x	0.0%	0.0%	-7.9%
ATOS	n/a	0.0x	0.4x	0.0%	0.0%	-211.9%
Peer median	n/a	0.0x	n/a	0.0%	0.0%	-80.7%

Frequently asked questions about GT Biopharma Inc (GTBP)

Is GTBP stock a good investment?

The cached TradeMates AI model rates GT Biopharma Inc as AVOID with an investment score of 22/100. The AI model avoids GTBP due to an imminent cash crunch, a track record of severe earnings misses, and a 1-employee operational structure that lacks the scale for commercialization without a partner. This is algorithmic model output, not personal investment advice.

Is GTBP stock a buy?

The TradeMates model verdict for GTBP is AVOID with an investment score of 22/100. Treat this as a model signal to review, not a personal buy recommendation.